세계의 살부타몰 원료의약품(API) 시장 보고서(2025년)

Salbutamol active pharmaceutical ingredient (API) is the pure, pharmacologically active component that delivers the intended therapeutic effect in medications used for treating respiratory disorders. It serves as the foundational compound utilized by pharmaceutical manufacturers in producing finished dosage forms such as inhalers, tablets, and syrups.

The primary variants of salbutamol active pharmaceutical ingredient (API) include salbutamol sulfate and levalbuterol hydrochloride. Salbutamol sulfate, the sulfate salt form of salbutamol, acts as a rapid-onset bronchodilator, alleviating symptoms of asthma and other obstructive airway conditions by relaxing airway muscles. These APIs are formulated into inhalation solutions, tablets, syrups, and other dosage forms and are made available through hospital pharmacies, retail pharmacies, and online platforms. They are indicated for conditions such as asthma, chronic obstructive pulmonary disease (COPD), bronchospasm, among others, and are used by end-users like pharmaceutical companies, research institutions, and others.

The salbutamol active pharmaceutical ingredient (API) market research report is one of a series of new reports from The Business Research Company that provides salbutamol active pharmaceutical ingredient (API) market statistics, including the salbutamol industry global market size, regional shares, competitors with the salbutamol active pharmaceutical ingredient (API) market share, detailed salbutamol active pharmaceutical ingredient (API) market segments, market trends, and opportunities, and any further data you may need to thrive in the salbutamol active pharmaceutical ingredient (API) industry. This salbutamol active pharmaceutical ingredient (API) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The salbutamol active pharmaceutical ingredient (API) market size has grown strongly in recent years. It will grow from $2.86 billion in 2024 to $3.05 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The expansion during the historical period was supported by a growing prevalence of respiratory illnesses, an aging demographic, increased availability of generic medications, a rise in healthcare infrastructure, and heightened levels of environmental pollution.

The salbutamol active pharmaceutical ingredient (API) market size is expected to see strong growth in the next few years. It will grow to $3.90 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The projected growth is attributed to worsening air quality, increasing rates of asthma and COPD, escalating demand for generics, growing healthcare spending, and the development of healthcare infrastructure. Prominent trends anticipated in the coming years include progress in eco-friendly chemical processes, greater adoption of automated production systems, enhanced use of process analytical technology (PAT), innovations in metered-dose inhaler technologies, and the emergence of individualized dosing formats.

The rising incidence of respiratory diseases is expected to drive the growth of the salbutamol active pharmaceutical ingredient (API) market in the coming years. Respiratory conditions affect the lungs and airways, leading to breathing difficulties and reduced oxygen intake. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and other lung infections. The growing number of respiratory cases is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and impair lung function. Salbutamol API plays a vital role in treating these conditions by helping to open the airways, providing quick relief from symptoms such as wheezing and shortness of breath, and improving overall respiratory function and patient health. For example, in November 2024, the Australian Bureau of Statistics reported that in 2022, approximately 2.8 million Australians-about 11% of the population-were living with asthma. Asthma accounted for 2.5% of the total disease burden and 35% of the respiratory disease burden in 2023, making it the leading cause of disease burden among children aged 1-9 years. Consequently, the increasing prevalence of respiratory diseases is fueling the demand for salbutamol API.

Companies operating in the salbutamol API market are increasingly focusing on innovative drug formulations, such as eco-friendly inhalers, to align with environmental standards and offer sustainable treatment solutions. These inhalers utilize propellants with low global warming potential or are designed as propellant-free systems, such as dry powder inhalers. For instance, in November 2023, GSK plc, a UK-based pharmaceutical company, advanced its low-carbon Ventolin inhaler to Phase III trials. This inhaler uses a next-generation propellant that reduces emissions by 90%. Ventolin is a brand of inhalers containing salbutamol (also known as albuterol), which works by opening the airways to provide relief from asthma and other respiratory issues. The company's sustainability initiative focuses on modifying the propellant used in the inhaler to reduce its environmental impact, while maintaining the same active ingredient-salbutamol API.

In October 2022, Lupin Limited, an India-based pharmaceutical company, acquired the rights to Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol from Sunovion Pharmaceuticals Inc. for $75 million. This acquisition enhances Lupin's respiratory product portfolio in the US market, strengthening its presence in the inhalation therapy segment and improving its capability to support patients with chronic respiratory conditions. Sunovion Pharmaceuticals Inc. is a US-based firm known for its expertise in respiratory treatments, including those based on the salbutamol active pharmaceutical ingredient (API) for asthma and COPD.

Major players in the salbutamol active pharmaceutical ingredient (api) market are Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Amphastar Pharmaceuticals Inc., FDC Limited, Neuland Laboratories Ltd., Melody Healthcare Pvt. Ltd., Supriya Lifescience Ltd., Lusochimica S.p.A., Intas Pharmaceuticals ltd, Olon S.p.A., VIVAN Life Sciences, Vamsi Labs Ltd., Aarti Pharmalabs Ltd., Jayco Chemical Industries, Orex Pharma Pvt. Ltd., Enomark, Chemcopia, and Cerata Pharma.

North America was the largest region in the salbutamol active pharmaceutical ingredient (API) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in salbutamol active pharmaceutical ingredient (API) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the salbutamol active pharmaceutical ingredient (API) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The salbutamol active pharmaceutical ingredient (API) market consists of sales of nebulizer solutions, raw salbutamol powder, and injectable salbutamol formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Salbutamol active pharmaceutical ingredient (API) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on salbutamol active pharmaceutical ingredient (api) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for salbutamol active pharmaceutical ingredient (api) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The salbutamol active pharmaceutical ingredient (api) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Salbutamol Sulfate; Levalbuterol Hydrochloride
• 2) By Formulation Type: Inhalation Solutions; Tablet Formulations; Syrup Formulations; Other Delivery Methods
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Bronchospasm; Other Applications
• 5) By End-User: Pharmaceutical Companies; Research Laboratories; Other End Users
• Subsegments:
• 1) By Salbutamol Sulfate: Inhalation Powder; Inhalation Solution; Oral Tablets; Oral Syrup; Injectable Form
• 2) By Levalbuterol Hydrochloride: Inhalation Solution; Metered Dose Inhaler (MDI); Oral Solution; Nebulizer Solution
• Companies Mentioned: Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Lupin Limited; Amphastar Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Salbutamol Active Pharmaceutical Ingredient (API) Market Characteristics

3. Salbutamol Active Pharmaceutical Ingredient (API) Market Trends And Strategies

4. Salbutamol Active Pharmaceutical Ingredient (API) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Salbutamol Active Pharmaceutical Ingredient (API) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Salbutamol Active Pharmaceutical Ingredient (API) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Growth Rate Analysis
• 5.4. Global Salbutamol Active Pharmaceutical Ingredient (API) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Salbutamol Active Pharmaceutical Ingredient (API) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Salbutamol Active Pharmaceutical Ingredient (API) Total Addressable Market (TAM)

6. Salbutamol Active Pharmaceutical Ingredient (API) Market Segmentation

• 6.1. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salbutamol Sulfate
• Levalbuterol Hydrochloride
• 6.2. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhalation Solutions
• Tablet Formulations
• Syrup Formulations
• Other Delivery Methods
• 6.3. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Bronchospasm
• Other Applications
• 6.5. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Research Laboratories
• Other End Users
• 6.6. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Salbutamol Sulfate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhalation Powder
• Inhalation Solution
• Oral Tablets
• Oral Syrup
• Injectable Form
• 6.7. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Levalbuterol Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhalation Solution
• Metered Dose Inhaler (MDI)
• Oral Solution
• Nebulizer Solution

7. Salbutamol Active Pharmaceutical Ingredient (API) Market Regional And Country Analysis

• 7.1. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market

• 8.1. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Salbutamol Active Pharmaceutical Ingredient (API) Market

• 9.1. China Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 9.2. China Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Salbutamol Active Pharmaceutical Ingredient (API) Market

• 10.1. India Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market

• 11.1. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 11.2. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 12.1. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 13.1. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market

• 14.1. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 14.2. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market

• 15.1. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 15.2. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Salbutamol Active Pharmaceutical Ingredient (API) Market

• 16.1. UK Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market

• 17.1. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Salbutamol Active Pharmaceutical Ingredient (API) Market

• 18.1. France Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market

• 19.1. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market

• 20.1. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market

• 21.1. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 21.2. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 22.1. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Salbutamol Active Pharmaceutical Ingredient (API) Market

• 23.1. North America Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 23.2. North America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Salbutamol Active Pharmaceutical Ingredient (API) Market

• 24.1. USA Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 24.2. USA Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market

• 25.1. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 25.2. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Salbutamol Active Pharmaceutical Ingredient (API) Market

• 26.1. South America Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 26.2. South America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market

• 27.1. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market

• 28.1. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 28.2. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market

• 29.1. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 29.2. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Landscape And Company Profiles

• 30.1. Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Landscape
• 30.2. Salbutamol Active Pharmaceutical Ingredient (API) Market Company Profiles
  • 30.2.1. Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Cipla Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amphastar Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Salbutamol Active Pharmaceutical Ingredient (API) Market Other Major And Innovative Companies

• 31.1. FDC Limited
• 31.2. Neuland Laboratories Ltd.
• 31.3. Melody Healthcare Pvt. Ltd.
• 31.4. Supriya Lifescience Ltd.
• 31.5. Lusochimica S.p.A.
• 31.6. Intas Pharmaceuticals ltd
• 31.7. Olon S.p.A.
• 31.8. VIVAN Life Sciences
• 31.9. Vamsi Labs Ltd.
• 31.10. Aarti Pharmalabs Ltd.
• 31.11. Jayco Chemical Industries
• 31.12. Orex Pharma Pvt. Ltd.
• 31.13. Enomark
• 31.14. Chemcopia
• 31.15. Cerata Pharma

32. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Salbutamol Active Pharmaceutical Ingredient (API) Market

34. Recent Developments In The Salbutamol Active Pharmaceutical Ingredient (API) Market

35. Salbutamol Active Pharmaceutical Ingredient (API) Market High Potential Countries, Segments and Strategies

• 35.1 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer